Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone

Pharmacogenomics Journal

Volumn 3, Issue 6, 2003, Pages 356-361

  Yamanouchi, Y ^a   Iwata, Nakao ^a   Suzuki, T ^a   Kitajima, T ^a   Ikeda, M ^a   Ozaki, N ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Catechol O methyltransferase; Dopamine D2 receptor; Haplotype analysis; Risperidone; Schizophrenia; Serotonin 2A receptor

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; LEVOMEPROMAZINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; JAPAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SAMPLE SIZE; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; TASK PERFORMANCE;

ADULT; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 0346025677     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500211     Document Type: Article

References (31)

1. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-546.
2. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21: 106S-115S.
3. Stober G, Jatzke S, Heils A, Jungkunz G, Knapp M, Mossner R et al. Insertion/deletion variant (-141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. Short communication. J Neural Transm 1998; 105: 101-109.
4. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 1993; 2: 2197.
5. Suzuki A, Kondo T, Mihara K, Furukori H, Nagashima U, Ono S et al. Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 1105-1113.
6. Suzuki A, Kondo T, Mihara K, Yasui-Furukori N, Ishida M, Furukori H et al. The - 141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545-550.
7. Inayama Y, Yoneda H, Sakai T, Ishia T, Nonomura Y, Kono Y et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996; 67: 103-105.
8. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346:281-282.
9. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997; 68: 2186-2193.
10. Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000; 47: 252-266.
11. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002; 159: 1593-1595.
12. Egan MF, Goldberg TE, Kolachana BS, Callicot JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
13. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
14. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000; 31: 342-349.
15. Niu T, Qin ZS, Xu X, Liu JS. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 2002; 70: 157-169.
16. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
17. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998; 3: 42-49.
18. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225-229.
19. Veenstra-VanderWeele J, Kim SJ, Lord C, Courchesne R, Akshoomoff N, Leventhal BL et al. Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet 2002; 114: 277-283.
20. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
21. Pohjalainen T, Nagren K, Syvalahti EK, Hietala J. The dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 1999; 9: 505-509.
22. Thompson J, Thomas N, Singleton A, Piggot M, Lloyd S, Perry EK et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
23. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48: 648-654.
24. Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am J Med Genet 1997; 74: 162-166.
25. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
26. Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 1998; 3: 261-265.
27. Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003; 13: 183-185.
28. Kay SR, Opler LA, Spitzer RL, Williams JB, Fiszbein A, Gorelick A. SCID-PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry 1991; 32: 355-361.
29. Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ et al. Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biol Psychiatry 1996; 40: 1267-1272.
30. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
31. Weir BS Genetic Data Analysis II. Sinauer Associates: Sunderland, MA, 1996.